skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Sponsored by:

SCRIP AWARDS 2022 SHORTLIST ANNOUNCED!
click here to view the shortlist

Now in its 18th year, the Scrip Awards brings together over 400 industry leaders to celebrate and recognise the very best innovations and achievements in global biopharma. Winners will be celebrated across 15 categories, covering a full spectrum of advancements, from Best New Drug, Community Partnership of the Year, Clinical Advance of the Year and Best Contract Research Organisation.

KEY DETAILS
  • Ceremony 30 November 2022
  • Free to enter
  • Royal Lancaster, London

All Awards entries will be carefully reviewed by an independent Judging Panel - a group of senior industry experts from around the world, handpicked for their experience and objectivity. This prestigious annual event of networking and celebration will incorporate a gala black-tie dinner and Awards ceremony, on Wednesday 30 November at the Royal Lancaster Hotel, London.

The shortlist has been announced!

The Scrip Awards Shortlist 2022

Download All

Best New Drug Award

Sponsored by

The Best New Drug Award recognises excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.

NOMINEES:

  • Agios Pharmaceuticals’ Pyrukynd (mitapivat) forpyruvate kinase deficiency
  • Argenx’s Vyvgart (efgartigimod alfa) for generalized myasthenia gravis
  • Immunocore’s Kimmtrak (tebentafusp) for metastatic uveal melanoma
  • Legend Biotech/Janssen Biotech’s Carvykti (ciltacabtagene autoleucel) for multiple myeloma
  • Mirum Pharmaceuticals’ Livmarli (maralixibat) for cholestatic pruritus in patients with Alagille syndrome
  • Servier Pharmaceuticals’ Tibsovo (ivosidenib tablets) for cholangiocarcinoma with an IDH1 mutation
Read about these finalists

Who can Enter

Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.

Clinical Advance of the Year

Sponsored by

This Award seeks to recognise success in a clinical trial of a new drug product (biological or chemical) which is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

NOMINEES:

  • Boehringer Ingelheim and Eli Lilly’s Phase III EMPEROR-Preserved trial of Jardiance in heart failure
  • Daiichi Sankyo and AstraZeneca’s Phase III DESTINY-Breast04 trial of Enhertu in breast cancer
  • Intellia Therapeutics’ Phase Itrial of NTLA-2001for transthyretin amyloidosis
  • Janssen Oncology’s Phase I/II MajesTEC-1 study of teclistamab in multiple myeloma
  • Lumosa Therapeutics’ Phase IIa study of LT3001 for stroke
  • Servier’s Phase III AGILE trial of Tibsovo in IDH1-mutated AML
Read about these finalists

Who can Enter

Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.

WuXi AppTec’s Biotech Company of the Year

Sponsored by

The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This Award honours outstanding achievement by biotech companies

NOMINEES:

  • Bicycle Therapeutics
  • Immunocore
  • Moderna
  • Qlaris Bio
  • Redx Pharma
  • SparingVision

Who can Enter

The winner of the Biotech Company of the Year Award will be the biotech firm which has achieved the most in the 12 months between 1 June 2021 - 30 June 2022. For example, this could be moving the business from an early stage, to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.

China Biopharma Leadership Award

Sponsored by

Scrip’s China Biopharma Leadership Award reflects on the rapid maturing of China’s biopharma sector - thanks to the development of Homegrown biopharma companies, CDMOs, and increasing investment from global multinational biopharma companies. The category seeks to reward firms that have shown leadership in developing China’s biopharma sector through significant commercial and R&D activity, and by helping patients access new treatments, through new launches and successful negotiations with China’s healthcare payers and clinical leaders.

NOMINEES:

To enter this category, please answer the following:

  • Anticancer Bioscience
  • BeiGene China
  • Brii Biosciences
  • Clover Biopharmaceuticals
  • Everest Medicines

Who can Enter

This Award is open to any research-based pharmaceutical company either headquartered in China or with a significant presence in the market through its own investment or via a major partnership.

The judges will be looking for excellent performance across business activities achieved between 1 June 2021 - 30 June 2022. This could include a range of leadership activities, from launching new products, or signing a transformative new commercial deal or working with Chinese authorities on innovation in healthcare and patient access.

Community Partnership of the Year

Sponsored by

This Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organisation.

NOMINEES:

  • Agios Pharmaceuticals’ RISE UP clinical trial recruitment campaign with Sickle Cell Warriors
  • AstraZeneca's Young Health Programme in partnership with Plan International UK for the Girls Belong Here campaign
  • AstraZeneca and Deloitte’s Non-Executive Director Programme
  • PHASTAR and the Florence Nightingale Museum
  • Regeneron and the Society for Science’s Science Talent Search initiative
Read about these finalists

Who can Enter

The judges will be looking for effective partnership activity which took place between 1 June 2021 - 30 June 2022, to the benefit of humankind. For example, these types of partnerships could include patient and carer support programs, educational programs or disease awareness campaigns or even a social media campaign that went viral.

Executive of the Year

Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies.

NOMINEES:

Executive Of The Year – Companies with a market cap >$7bn

  • Stéphane Bancel, Chief Executive Officer of Moderna
  • Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
  • Ying Huang, Chief Executive Officer of Legend Biotech
  • Husseini Manji, Global Head of Johnson & Johnson Science for Minds
  • Christi Shaw, Chief Executive Officer of Kite, a Gilead Company
  • Jan van de Winkel, President & Chief Executive Officer of Genmab

Executive Of The Year – Private companies and those with a market cap <$7bn

  • Renée Aguiar-Lucander, Chief Executive Officer of Calliditas Therapeutics
  • Stéphane Boissel, Chief Executive Officer and Chairman of SparingVision
  • Scott Braunstein, Chief Executive Officer of Marinus Pharmaceuticals
  • Bahija Jallal, Chief Executive Officer of Immunocore
  • John Leonard, President and Chief Executive Officer of Intellia Therapeutics
  • Michael M Morrissey, President and Chief Executive Officer of Exelixis
Read about these finalists

Who can Enter

This year’s winner will be the executive who has exhibited exemplary leadership throughout the year from 1 June 2021 - 30 June 2022. This could range from leading an emerging company to an established place within the industry, to turning around the fortunes of a failing company or unit, or leading a firm successfully through the turbulence of a merger or acquisition. Also important to the judges will be the executive’s career achievements, influence within the industry and leadership qualities. To be eligible for this year’s Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.

Licensing Deal of the Year

Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing.

NOMINEES:

  • Accord Healthcare with Myovant Sciences to commercialize Orgovyx(relugolix) for advanced hormone-sensitive prostate cancer
  • AstraZeneca and Ionis Pharmaceuticals for the development and commercialization of eplontersen for TTR amyloidosis
  • GSK and Alector for the development and commercialization of AL001 and AL101for neurodegenerative diseases
  • iTeos and GSK for the development and commercialization of EOS-448 (GSK4428859A) for solid tumors
  • RQ Biotechnology and AstraZeneca for novel monoclonal antibodies targeting SARS-CoV-2
  • Sunovion Pharmaceuticals (Sumitomo Pharma) and Otsuka Pharmaceutical to jointly develop and commercialize ulotaront, non-racemic amisulpride, SEP-378614 and SEP-380135
Read about these finalists

Who can Enter

In choosing the winner of Scrip’s Licensing Deal of the Year Award, the judges will look at all aspects of the submitted transactions, from their monetary and strategic value, to The benefits they give to both sides. To qualify, licensing deals must have been closed between 1 June 2021 - 30 June 2022.

Business Development Team of the Year

Scrip’s Business Development Team of the Year Award will honour the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.

NOMINEES:

  • Beam Therapeutics’ Business Development Team
  • Domainex’s Business Development and Commercial Team
  • Healiva’s Business Development Team
  • Sanofi Partnering Team
  • Synaffix’s Business Development Team
  • Takeda's Center for External Innovation
Read about these finalists

Who can Enter

This Award will go to a team that is truly much more than the sum of its parts. The Judges will be looking for strong performance across a number of criteria, such as achievement of short and long-term goals, and good communication of a shared vision.

Best Contract Research Organization - Full service providers

The Award for the Best Contract Research Organization acknowledges the critical role that CROs play in drug development. Outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials and other research.

NOMINEES:

  • Altasciences
  • CMIC Group
  • ICON
  • IQVIA
  • Novotech
  • Parexel
  • PPD, Part of Thermo Fisher Scientific
  • Syneos Health
Read about these finalists

Who can Enter

This Award is for the companies who provide the full range of services to their clients; and they will be judged on the quality of services and relationships they have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal. To qualify, candidates must draw on their achievements in the year between 1 June 2021 - 30 June 2022.

Best Contract Research Organisation – Specialist Providers

The Award for the Best Contract Research Organisation acknowledges the critical role that CROs play in drug development. Outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials and other research.

NOMINEES:

  • Cellomatics Biosciences
  • CluePoints
  • Crown Bioscience
  • MAC Clinical Research
  • Medical Research Network
  • MMS Holdings
  • PHASTAR
  • Veramed

Who can Enter

This Award for those companies who provide niche services to their clients will be judged on the quality of services and relationships they have built with their clients. To qualify, candidates must draw on their achievements in the year between 1 June 2021 - 30 June 2022.

Quris Partnership Alliance Award

Sponsored by

Scrip’s Best Partnership Alliance Award recognises the importance of pharmaceutical and/ or biotech companies working together to develop new medicines. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in developing new drugs.

NOMINEES:

  • Amgen and Arrakis Therapeutics for the discovery of RNA degraders
  • GRAIL and AstraZeneca for the research, development and commercialization of companion diagnostic assays for early-stage cancer
  • Merck KGaA and Amphista Therapeuticsto discover and develop small-molecule protein degraders in oncology and immunology indications
  • Recursion and Roche/Genentech to use Recursion’sAI Operating System and Maps of Biologyto identify novel biological relationships in neuroscience and oncology
  • Sanofi and IGM Biosciencesfor engineered IgM antibodies in oncology and immunology/inflammationtargets
  • SparingVision and Intellia Therapeuticsto develop novel genomic medicines using CRISPR/Cas9 technology for ocular diseases

Who can Enter

The judges will be focusing on deals that require strong strategic input from both partners, involving business development, joint marketing/promotion or joint R&D. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure. Partnerships must have been announced, or have achieved a significant milestone, between 1 June 2021 - 30 June 2022, and entrants should be able to show some sustained benefits from the deal. Please note, deals between majority or wholly owned subsidiaries and their parent companies are not eligible for this Award.

Private Financing Deal Of The Year

This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech companies. The investment can come in a variety of guises from grants and public private partnership deals to venture fundraising and public offerings but should be earmarked for use in drug discovery and/or development.

NOMINEES:

  • Engitix Therapeutics’ $54m Series A financing
  • Mestag Therapeutics’ $45m seed funding
  • Microbiotica’s£50m Series B financing
  • OMass Therapeutics’ $100m Series B financing
  • Precirix’s€80m Series B financing
  • SalioGen Therapeutics’$130mSeries B financing
Read about these finalists

Who can Enter

This award is open only to companies actually raising the funds (i.e., not bankers or agents). To be eligible, all financing must have been announced between 1 June 2021 - 30 June 2022

MSD’s Innovation Award

Sponsored By

This category will acknowledge and celebrate the outstanding scientific or technological breakthrough which the judging believes has the potential to be transformative in the discovery or development of new medicines.

NOMINEES:

  • 3DBio’s AuriNovo patient-matched, 3D-bioprinted living tissue ear implant
  • BenevolentAI’sBenevolent Platform with Benevolent Knowledge Graph
  • Evonetix’s desktop platform for DNA synthesis
  • Nucleome Therapeutics’ genome dark matter platform technology
  • Orca Bio’s Orca-Tcell therapy
  • Quris BioAI Clinical Prediction Platform
Read about these finalists

Who can Enter

The Award is open to any person, group or company that has achieved a genuinely Groundbreaking advance during the qualifying period of 1 June 2021 - 30 June 2022. We welcome entries that are active in the life sciences ecosystem – from early-stage research through to clinical proof-of-concept developments. Achievements we wish to recognise include: insights that advance our understanding of disease biology; new therapeutic targets or approaches; elucidation of a novel mechanism of action; clinical proof of concept of a novel mechanism or novel target; and techniques and technology platforms that enhance the medical benefits of new or existing medicines.

Pharma Company of the Year

Sponsored by

The Pharma Company of the Year Award honours outstanding achievements by pharmaceutical companies over the qualifying 12 months between 1 June 2021 - 30 June 2022.

NOMINEES:

To be announced on the evening

Lifetime Achievement Award

Sponsored by

The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career. This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry.

NOMINEES:

To be announced on the evening

Who can Enter

Nominees may be retired or semi-retired but will still be active in the industry in some capacity. For this special Award, candidates must be nominated by a third party. The nomination should outline in no more than 750 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.

The scrip awards Shortlist 2022

view the 2022 shortlist video below

The Judges

Want to sponsor an award?

Sponsorship provides a wealth of opportunities, from thought leadership, to brand awareness and lead generation. Find out more about the numerous sponsorship opportunities available.

Sponsor Opportunities

BOOK A TABLE

Looking to attend the Scrip Awards? Book your table today for the awards!

BOOK YOUR TABLE

Headline Sponsor

ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.

our 2022 sponsors

Avance Clinical is a premium full-service Contract Research Organisation (CRO) based in Australia, New Zealand and North America, providing high-quality clinical research services to the international drug development industry which brings innovative new drugs to patients. Avance Clinical has more than 260 staff and has backing from the private equity group, Riverside Company, to support global expansion plans.

Avance Clinical offers clinical project management, trial monitoring, regulatory support, safety reporting, scientific and medical writing, data management, statistical and pharmacokinetic services, and external clinical auditing. We operate to the highest standards of compliance required by global regulatory agencies such as the FDA to ensure acceptance of data for drug approvals.

Our clients are international biotech companies in their early phases of drug development that require fast, agile, and adaptive solution-oriented clinical research services. The company uses state-of-the-art technology, gold standard systems, and deep scientific expertise to provide clients with the most successful outcomes.

The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. www.iqvia.com.

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. In 2019 MSD had sales of more than $46 billion and we operate in more than 140 countries.

Parexel partners with life science and biopharmaceutical customers across the globe to help transform scientific discoveries into innovative new therapies that improve patient health. Our full-service offerings span early phase to post-marketing approval and include expert consultation across regulatory and consulting, laboratory services, real-world evidence, market access and more. With more than 35 years of experience, our therapeutic, technical and functional abilities are underpinned by a deep conviction In what we do best: supporting our customers in fulfilling the unmet medical needs of patients worldwide.

Quris is an artificial intelligence innovator that is disrupting the drug development process. Quris' Bio-AI Clinical Prediction Platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials. We are led by a team of top scientists and strategic investors and are actively preparing for clinical testing with our first AI-based drug.

Thermo Fisher Scientific provides industry-leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers through our Patheon brand. With more than 65 locations around the world, we provide integrated, end-to-end capabilities across all phases of development, including API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics services and commercial manufacturing and packaging. Built on a reputation for scientific and technical excellence, we provide pharma and biotech companies of all sizes instant access to a global network of facilities and experts across the Americas, Europe, Asia and Australia. We offer integrated drug development and clinical services tailored to fit your drug development journey through our Quick to Care™ program. Our Quick to Clinic™ programs for large and small molecules help you balance speed and risk during early development so you can file your IND quickly and successfully. Digital innovations such as our mysupply Platform and Pharma 4.0 enablement offer real-time data and a streamlined experience. Together with our customers, we’re rapidly turning pharmaceutical possibilities into realities.

Today, WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials.

WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,600 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

PREVIOUS SCRIP AWARD CEREMONIES

The Scrip Awards are now in the 18th year of connecting hundreds of pioneers in global healthcare. Take a look back at our previous Awards and winners.

2021
Scrip Awards 2021

2nd December, 2021

2020
Scrip Awards 2020

Virtual ceremony 2020

2019
Scrip Awards 2019

4th December, 2019

got a question about the awards?

Please enter your name
Please enter your email
Please enter your valid email
Please enter your question
Please accept the terms & conditions
Senior Events Manager

jo.kirkpatrick@informa.com